Biotech 2050 Podcast

Leading personalized immune medicines, Harlan Robins, CSO & Co-Founder, Adaptive Biotechnologies


Listen Later

Synopsis:
Harlan Robins, Ph.D., is the CSO and Co-Founder of Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune profiling platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Harlan discusses how he navigated the ups and downs of co-founding a company. He talks about the adaptive immune system, why it’s important, and what Adaptive is currently working on from a development perspective. He also discusses Adaptive’s partnership with Genentech to create personalized cancer therapies.
Biography:
Dr. Harlan Robins is the Chief Scientific Officer and Co-Founder of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease.
Prior to co-founding Adaptive, Harlan served in various roles at the Fred Hutchinson Cancer Research Center (FHCRC) in the Computational Biology Program, including Assistant Faculty Member, Associate, and Full Member and Head of the program.
Harlan holds a BS in Physics from Harvard University and a master’s degree and PhD in Physics from the University of California, Berkeley, with a visiting appointment to the California Institute of Technology. Harlan received postdoctoral appointments in the particle theory group at the Weizmann Institute of Science in Israel.
Interested in the mathematics behind genetics and observing the potential utility of high-level mathematics to study problems in the biological sciences, Harlan took another postdoctoral appointment at the Institute for Advance Study in Princeton under famed biologist Dr. Arnold Levine. With Dr. Levine, he concentrated on developing bioinformatic algorithms for micro RNA targets and bacterial genome analysis, a precursor to his faculty appointment at FHCRC in the Computational Biology Group, Public Health Sciences and Human Biology Divisions.
...more
View all episodesView all episodes
Download on the App Store

Biotech 2050 PodcastBy Biotech 2050

  • 4.7
  • 4.7
  • 4.7
  • 4.7
  • 4.7

4.7

59 ratings


More shows like Biotech 2050 Podcast

View all
WSJ Your Money Briefing by The Wall Street Journal

WSJ Your Money Briefing

1,716 Listeners

Exchanges by Goldman Sachs

Exchanges

979 Listeners

The Knowledge Project with Shane Parrish by Shane Parrish

The Knowledge Project with Shane Parrish

2,658 Listeners

Odd Lots by Bloomberg

Odd Lots

1,856 Listeners

Masters of Scale by WaitWhat

Masters of Scale

3,989 Listeners

The Long Run with Luke Timmerman by Timmerman Report

The Long Run with Luke Timmerman

122 Listeners

The Readout Loud by STAT

The Readout Loud

316 Listeners

The Intrinsic Value Podcast - The Investor’s Podcast Network by The Investor's Podcast Network

The Intrinsic Value Podcast - The Investor’s Podcast Network

559 Listeners

Business Of Biotech by Ben Comer

Business Of Biotech

88 Listeners

BioCentury This Week by BioCentury

BioCentury This Week

30 Listeners

Raising Health by Andreessen Horowitz, a16z Bio + Health

Raising Health

144 Listeners

Business Breakdowns by Colossus | Investing & Business Podcasts

Business Breakdowns

349 Listeners

Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

18 Listeners

The So What from BCG by Boston Consulting Group BCG

The So What from BCG

220 Listeners

HBR On Leadership by Harvard Business Review

HBR On Leadership

161 Listeners